NVX-412, a New Oncology Drug Candidate, Induces S-Phase Arrest and DNA Damage in Cancer Cells in a p53-Independent Manner

The new molecular entity quinoxalinhydrazide derivative NVX-412 was identified as a promising drug candidate for the treatment of various cancer types due to its strong cytotoxic activity and relative specificity. Here, we provide first data about the mechanisms of action of NVX-412. We show that NV...

Descripción completa

Detalles Bibliográficos
Autores principales: Hebar, Alexandra, Rütgen, Barbara C., Selzer, Edgar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441706/
https://www.ncbi.nlm.nih.gov/pubmed/23028738
http://dx.doi.org/10.1371/journal.pone.0045015

Ejemplares similares

Ejemplares similares